Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.
- Published in:
- Oncology, 2016, v. 91, n. 5, p. 251, doi. 10.1159/000448621
- By:
- Publication type:
- Article
Works matching AU Hynes, Scott M.
Results: 10
1
2
Disposition of [<sup>14</sup>C]LY2606368 following intravenous administration in patients with advanced and/or metastatic solid tumours.
- Published in:
- Xenobiotica, 2020, v. 50, n. 7, p. 793, doi. 10.1080/00498254.2019.1702736
- By:
- Publication type:
- Article
3
Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
4
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
5
Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.
- Published in:
- Biopharmaceutics & Drug Disposition, 2015, v. 36, n. 1, p. 49, doi. 10.1002/bdd.1922
- By:
- Publication type:
- Article
6
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m<sup>2</sup> every 21 days in patients with cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 1, p. 136, doi. 10.1007/s10637-012-9815-9
- By:
- Publication type:
- Article
7
Effect of a Supratherapeutic Dose of Omaveloxolone on the Corrected QT Interval in Healthy Participants: A Randomized, Double‐Blind, Placebo‐ and Active‐Controlled, Three‐Way Crossover Study.
- Published in:
- CTS: Clinical & Translational Science, 2025, v. 18, n. 2, p. 1, doi. 10.1111/cts.70139
- By:
- Publication type:
- Article
8
Understanding the mechanisms of food effect on omaveloxolone pharmacokinetics through physiologically based biopharmaceutics modeling.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 10, p. 1771, doi. 10.1002/psp4.13221
- By:
- Publication type:
- Article
9
Relative Bioavailability of Omaveloxolone When Capsules Are Sprinkled Over and Mixed in Applesauce Compared With Administration as Intact Omaveloxolone Capsules: A Phase 1, Randomized, Open‐Label, Single‐Dose, Crossover Study in Healthy Adults
- Published in:
- Journal of Clinical Pharmacology, 2024, v. 64, n. 10, p. 1304, doi. 10.1002/jcph.2482
- By:
- Publication type:
- Article
10
Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors.
- Published in:
- Xenobiotica, 2014, v. 44, n. 9, p. 827, doi. 10.3109/00498254.2014.900589
- By:
- Publication type:
- Article